首页> 外文期刊>Molecular cancer therapeutics >Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer
【24h】

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer

机译:靶向Emicoron的G-Quadreplex DNA结构具有强烈的抗肿瘤功效,免受人结肠癌的先进模型

获取原文
获取原文并翻译 | 示例
           

摘要

We previously identified EMICORON as a novel G-quadruplex (G4) ligand showing high selectivity for G4 structures over the duplex DNA, causing telomere damage and inhibition of cell proliferation in transformed and tumor cells. Here, we evaluated the antitumoral effect of EMICORON on advanced models of human colon cancer that could adequately predict human clinical outcomes. Our results showed that EMICORON was well tolerated in mice, as no adverse effects were reported, and a low ratio of sensitivity across human and mouse bone marrow cells was observed, indicating a good potential for reaching similar blood levels in humans. Moreover, EMICORON showed a marked therapeutic efficacy, as it inhibited the growth of patient-derived xenografts (PDX) and orthotopic colon cancer and strongly reduced the dissemination of tumor cells to lymph nodes, intestine, stomach, and liver. Finally, activation of DNA damage and impairment of proliferation and angiogenesis are proved to be key determinants of EMICORON antitumoral activity. Altogether, our results, performed on advanced experimental models of human colon cancer that bridge the translational gap between preclinical and clinical studies, demonstrated that EMICORON had an unprecedented antitumor activity warranting further studies of EMICORON-based combination treatments. (C) 2015 AACR.
机译:我们以前将Emicoron鉴定为新型G-Quadreple(G4)配体,显示在双相DNA上的G4结构的高选择性,导致转移和肿瘤细胞中的端粒损伤和抑制细胞增殖。在这里,我们评估了Emicoron对人性结肠癌高级模型的抗肿瘤作用,可以充分预测人类临床结果。我们的研究结果表明,埃米莫伦在小鼠中耐受良好,因为没有报道不良反应,观察到人和小鼠骨髓细胞对人和小鼠骨髓细胞的敏感性的低比率,表明达到人类类似血液水平的良好潜力。此外,Emicoron显示出明显的治疗效果,因为它抑制患者衍生的异种移植物(PDX)和原位结肠癌的生长,并且强烈降低了肿瘤细胞的传播给淋巴结,肠,胃和肝脏。最后,证明了DNA损伤的激活和增殖和血管生成的损伤是Emicoron抗肿瘤活性的关键决定因素。我们的结果,对人性结肠癌高级实验模型进行了桥接临床和临床研究的平移差距的先进实验模型,表明Emicoron具有前所未有的抗肿瘤活性,需要进一步研究基于Emicoron的组合治疗。 (c)2015年AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号